US-based Sealonix has received $20m in Series A financing for the development of sealant products for abdominopelvic and orthopaedic procedures.

Led by Excelestar Ventures, the round included participants AMED Ventures, Sparta Group, Iyengar Capital, J2 Ventures and TiE Boston.  

The funds raised in this round will also be utilised to expand the development team and carry out clinical trials.

Excelestar Ventures’ founding partner Tasneem Dohadwala will now serve on Sealonix’s board of directors.

Dohadwala said: “At Excelestar, we are excited to partner with Sealonix’s experienced team to bring this next-generation haemostatic sealant to market.”

Founded in January this year, Sealonix leverages its biomaterials expertise to develop advanced haemostatic sealants for surgical applications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Initially, the company is focused on the development of a sealant patch to offer rapid haemostasis for abdominopelvic and orthopaedic procedures.

The PramStat patch is engineered to absorb within one week after it is implanted.

Sealonix CEO Amar Sawhney said: “The PramStat patch builds on many years of research done by this experienced team, and now will move rapidly into clinical development.

“This capital will allow us to complete clinical development and pursue FDA approval. We look forward to bringing the most advanced device and method to control surgical bleeding to surgeons.”